| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jordi Llaudó, Lourdes Anta, Ignacio Ayani, Javier Martínez, Juan Schronen, Margarita Morozova, Mikhail Ivanov, Ibón Gutierr. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). International clinical psychopharmacology. vol 31. issue 6. 2017-11-27. PMID:27416102. |
the aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ism in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg). |
2017-11-27 |
2023-08-13 |
Not clear |
| Soode Tajik-Esmaeeli, Ehsan Moazen-Zadeh, Niloofar Abbasi, Seyed V Shariat, Farzin Rezaei, Bahman Salehi, Shahin Akhondzade. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. International clinical psychopharmacology. vol 32. issue 2. 2017-11-27. PMID:27941358. |
in this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4-6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. |
2017-11-27 |
2023-08-13 |
Not clear |
| Alper Bas, Gozde Gultekin, Said Incir, Tuba Ocek Bas, Murat Emul, Alaatin Dura. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. Psychiatry research. vol 247. 2017-11-17. PMID:27871032. |
the aim of this study is investigating the relationship between serum thioredoxin levels and cognitive functions in acute psychotic episode and remission state patients with schizophrenia; and examining whether there were differences between patients using clozapine and other atypical antipsychotics; including risperidone, olanzapine and amisulpride. |
2017-11-17 |
2023-08-13 |
Not clear |
| Hong Joon Lee, Jin-Sung Choi, Bok Hee Choi, Sang June Hah. Inhibition of cloned hERG potassium channels by risperidone and paliperidone. Naunyn-Schmiedeberg's archives of pharmacology. vol 390. issue 6. 2017-11-08. PMID:28265686. |
risperidone and one of its active metabolites, paliperidone, are widely used for the treatment of schizophrenia. |
2017-11-08 |
2023-08-13 |
Not clear |
| Kruti Joshi, Xiaoyun Pan, Rosa Wang, Erru Yang, Carmela Benso. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Current medical research and opinion. vol 32. issue 11. 2017-09-28. PMID:27479694. |
healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. |
2017-09-28 |
2023-08-13 |
Not clear |
| Kruti Joshi, Xiaoyun Pan, Rosa Wang, Erru Yang, Carmela Benso. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Current medical research and opinion. vol 32. issue 11. 2017-09-28. PMID:27479694. |
this retrospective longitudinal cohort study aimed to compare treatment patterns, healthcare resource utilization (hru), and costs in patients with schizophrenia treated with second-generation antipsychotic long-acting injectables (sga-lais): biweekly risperidone lai versus once-monthly paliperidone palmitate. |
2017-09-28 |
2023-08-13 |
Not clear |
| Haitao Wang, Mohd Farhan, Jiangping Xu, Philip Lazarovici, Wenhua Zhen. The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget. vol 8. issue 32. 2017-09-25. PMID:28881851. |
darpp-32 phosphorylation is increased upon therapy with antipsychotic drugs, such as haloperidol and risperidone which improve behavioral performance in experimental animal models and patients; v. genetic analysis of the gene coding for darpp-32 propose an association with schizophrenia. |
2017-09-25 |
2023-08-13 |
Not clear |
| Katharina Grau, Paul L Plener, Maximilian Gahr, Christian Denzer, Roland W Freudenman. Mild Hypothermia in a Child with Low-Dose Risperidone. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. vol 45. issue 4. 2017-08-28. PMID:27685194. |
risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation. |
2017-08-28 |
2023-08-13 |
Not clear |
| E Sacchetti, C Magri, A Minelli, P Valsecchi, M Traversa, S Calza, A Vita, M Gennarell. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. The pharmacogenomics journal. vol 17. issue 2. 2017-08-08. PMID:26856250. |
the grm7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. |
2017-08-08 |
2023-08-13 |
Not clear |
| E Sacchetti, C Magri, A Minelli, P Valsecchi, M Traversa, S Calza, A Vita, M Gennarell. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. The pharmacogenomics journal. vol 17. issue 2. 2017-08-08. PMID:26856250. |
because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (gwas) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia. |
2017-08-08 |
2023-08-13 |
Not clear |
| Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti, Toshihiko Kinoshit. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC psychiatry. vol 16. 2017-08-04. PMID:27236412. |
cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. |
2017-08-04 |
2023-08-13 |
Not clear |
| Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti, Toshihiko Kinoshit. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC psychiatry. vol 16. 2017-08-04. PMID:27236412. |
the present study aimed to compare the influence of risperidone lais (rlai) and paliperidone palmitate lais (pp) on cognitive function in outpatients with schizophrenia. |
2017-08-04 |
2023-08-13 |
Not clear |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. Journal of clinical psychopharmacology. vol 37. issue 3. 2017-08-04. PMID:28306616. |
optimal dosing of risperidone and olanzapine in the maintenance treatment for patients with schizophrenia and related psychotic disorders: a retrospective multicenter study. |
2017-08-04 |
2023-08-13 |
Not clear |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. Journal of clinical psychopharmacology. vol 37. issue 3. 2017-08-04. PMID:28306616. |
this study aims to determine the optimal tolerability dose ranges of risperidone (ris) and olanzapine (olz) administered during schizophrenia maintenance phase. |
2017-08-04 |
2023-08-13 |
Not clear |
| Sukhtej Sahni, B S Chavan, Ajeet Sidana, Priyanka Kalra, Gurjit Kau. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. The Indian journal of medical research. vol 144. issue 5. 2017-07-21. PMID:28361822. |
comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: a pilot study. |
2017-07-21 |
2023-08-13 |
Not clear |
| Sukhtej Sahni, B S Chavan, Ajeet Sidana, Priyanka Kalra, Gurjit Kau. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. The Indian journal of medical research. vol 144. issue 5. 2017-07-21. PMID:28361822. |
the current study was carried out to compare the efficacy and tolerability of clozapine versus risperidone in treatment-naive, first-episode patients of schizophrenia. |
2017-07-21 |
2023-08-13 |
Not clear |
| Ying Yang, Xiaojing Cheng, Qingzhi Xu, Renjun Li, Zengxun Liu, Liping Wang, Yanqing Zhang, Guoqiang Ren, Jintong Li. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arquivos de neuro-psiquiatria. vol 74. issue 10. 2017-06-28. PMID:27759808. |
the maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. |
2017-06-28 |
2023-08-13 |
Not clear |
| Robert E Davis, Christoph U Correl. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert review of neurotherapeutics. vol 16. issue 6. 2017-06-27. PMID:27042868. |
based on a large, placebo and risperidone controlled, phase-ii trial, iti-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia. |
2017-06-27 |
2023-08-13 |
Not clear |
| Geancarlo Zanatta, Gustavo Della Flora Nunes, Eveline M Bezerra, Roner F da Costa, Alice Martins, Ewerton W S Caetano, Valder N Freire, Carmem Gottfrie. Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations. ACS chemical neuroscience. vol 7. issue 10. 2017-06-21. PMID:27434874. |
risperidone is an atypical antipsychotic used in the treatment of schizophrenia and of symptoms of irritability associated with autism spectrum disorder (asd). |
2017-06-21 |
2023-08-13 |
Not clear |
| Alma Mihaljevic-Peles, Marina Sagud, Ivona Simunovic Filipcic, Vladimir Grosic, Ivana Pedisic, Robin Emsle. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatria Danubina. vol 28. issue 3. 2017-06-21. PMID:27658835. |
remission and employment status in schizophrenia and other psychoses: one-year prospective study in croatian patients treated with risperidone long acting injection. |
2017-06-21 |
2023-08-13 |
Not clear |